Key facts
- PCI Pharma Services’s last known valuation is $10.0B (Jul 2025).
- It has raised $1.5B across 1 recorded rounds; the latest was Secondary Transaction - Private in Jul 2025.
- Notable investors include Mubadala Investment Company, Blue Owl Capital, Bain Capital, Alberta Investment Management, Kohlberg & Company — 8 tracked in total.
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for PCI Pharma Services
Funding rounds
1 roundsAbout PCI Pharma Services
Provider of pharmaceutical contract development and manufacturing services intended to serve pharmaceutical and biotechnology companies worldwide. The company specializes in drug development support, clinical trial supply, contract drug manufacturing, sterile and non-sterile drug product packaging, and global pharmaceutical logistics, thereby enabling clients with coordinated and compliant support across the drug development and commercialization process.
- Industry
- BPO/Outsource Services
- Sector
- Business Products and Services (B2B)
- HQ
- Philadelphia, PA, United States
- Founded
- 1991
- Employees
- 7,500
- Website
- pci.com/
- Ownership
- Privately Held (backing)
PCI Pharma Services doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in PCI Pharma Services shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on PCI Pharma Services in its N-PORT filings yet. We sweep new filings monthly.